(RTTNews) - Neuronetics, Inc. (STIM), a neurohealth technology company, on Wednesday announced the publication of two significant peer-reviewed studies in the inaugural issue of the Transcranial Magnetic Stimulation journal, advancing the understanding of TMS therapy for depression.
The first study demonstrated that TMS improves a broad range of depressive symptoms, suggesting that TMS functions as a comprehensive treatment rather than targeting specific symptoms.
The analysis, which included 578 patients with major depressive disorder, showed equal effectiveness across three TMS protocols.
The second study compared the sensitivity of two depression assessment tools—PHQ-9 and QIDS-SR—and found that the PHQ-9 is more reliable in measuring improvements in depressive symptoms following TMS.
The PHQ-9 also identified higher remission rates and was more sensitive in capturing symptom changes.
Neuronetics continues to lead the field by providing valuable insights for clinicians to enhance the precision and effectiveness of TMS treatments.
Currently, STIM is trading at $3.19 up by 5.70%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
